171 related articles for article (PubMed ID: 23841097)
1. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice.
Kyttaris VC; Kampagianni O; Tsokos GC
Biomed Res Int; 2013; 2013():861028. PubMed ID: 23841097
[TBL] [Abstract][Full Text] [Related]
2. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.
Herber D; Brown TP; Liang S; Young DA; Collins M; Dunussi-Joannopoulos K
J Immunol; 2007 Mar; 178(6):3822-30. PubMed ID: 17339481
[TBL] [Abstract][Full Text] [Related]
3. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of receptor interacting protein kinase-1 (RIPK1) in the treatment of murine lupus.
Peng L; Wang P; Xu X; Chen D; Xu F; Yang F; Yang S; Xia H; Liu ZH; Qin W
Lupus Sci Med; 2024 Jun; 11(1):. PubMed ID: 38906550
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
9. T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.
Düster M; Becker M; Gnirck AC; Wunderlich M; Panzer U; Turner JE
Eur J Immunol; 2018 Aug; 48(8):1364-1375. PubMed ID: 29671873
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-25 is upregulated in patients with systemic lupus erythematosus and ameliorates murine lupus by inhibiting inflammatory cytokine production.
Li Y; Wang R; Liu S; Liu J; Pan W; Li F; Li J; Meng D
Int Immunopharmacol; 2019 Sep; 74():105680. PubMed ID: 31200339
[TBL] [Abstract][Full Text] [Related]
11. IL-33 neutralization suppresses lupus disease in lupus-prone mice.
Li P; Lin W; Zheng X
Inflammation; 2014 Jun; 37(3):824-32. PubMed ID: 24398614
[TBL] [Abstract][Full Text] [Related]
12. IL-17-producing T cells in lupus nephritis.
Apostolidis SA; Crispín JC; Tsokos GC
Lupus; 2011 Feb; 20(2):120-4. PubMed ID: 21303828
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
14. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice.
Song YC; Tang SJ; Lee TP; Hung WC; Lin SC; Tsai CY; Ng WV; Wu MF; Sun KH
Arthritis Rheum; 2010 Aug; 62(8):2401-11. PubMed ID: 20506162
[TBL] [Abstract][Full Text] [Related]
15. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
16. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
17. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
18. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
[TBL] [Abstract][Full Text] [Related]
19. Increased responsiveness of B. cells in the murine MRL/lpr model of lupus nephritis to interleukin-1 beta.
Lebedeva TV; Singh AK
J Am Soc Nephrol; 1995 Jan; 5(7):1530-4. PubMed ID: 7703391
[TBL] [Abstract][Full Text] [Related]
20. NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice.
Yougbare I; Keravis T; Lugnier C
Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):166019. PubMed ID: 33227426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
